Welcome Guest
Home » Reports » Oncology Drug Discovery Services Market, 2017-2030

Oncology Drug Discovery Services Market, 2017-2030

Published: Jun 21, 2017
Pages: 270
Product Code: RA10085
License Type :  (Learn More)

The early stages of research related to drug discovery, including the identification of a relevant target and a viable lead compound, play a crucial role in the overall success of a drug in preclinical and / or clinical studies. The process of drug discovery is extremely demanding, both in terms of capital expenses and time. Moreover, there is always a high risk of failure associated with R&D programs and, given the increasing regulatory stringency, the approval of new drugs has become significantly complex as well. Over the years, outsourcing has emerged as a popular trend in the pharmaceutical and biotechnology industry, and has demonstrated the potential to effectively cater to the growing demands associated with drug discovery as well. Contract Research Organizations (CROs), with dedicated teams of experts and innovative solutions across the various stages of the drug discovery and development process, are now located in all major global markets. Employing the services of these CROs offers a number of benefits to drug developers, including access to better technologies, latest R&D tools, cost and time savings and the potential to minimize risks associated with the drug discovery process.

 

Specifically, the oncology market, with an estimated global prevalence of 32 million, imposes a heavy burden on the healthcare system. There exists a significantly high unmet need for novel therapeutic options in this domain, translating into a growing demand for drug discovery initiatives. Therefore, CROs have now emerged as important stakeholders in the oncology market. The increasing trend towards outsourcing has triggered the establishment of several strategic collaborations between drug / therapy developers and CROs. In fact, several CROs have acquired other small / mid-sized CROs or collaborated with them for upgrading their own drug discovery capabilities in an effort to provide integrated services to its clients. Opportunities arising from the growth of personalized medicines, the vast unmet need for therapies for orphan indications, and the adoption of novel technology solutions, such as deep learning solutions, cloud-based technology platforms and 3D cell culture systems, are likely to act as some of the primary drivers of growth within this sector.

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The “Oncology Drug Discovery Services Market, 2017-2030” report features an extensive study of the current market landscape and the future potential of CROs providing drug discovery services in oncology. Cancer, one of the leading causes of death worldwide, is an extremely complex disease and medical science is still struggling to figure out the various factors associated with the disease’s origin, propagation, spread (metastasis) and relapse. In fact, in 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer.

 

With the increasing complexity of drug discovery and development process, the overall spending on R&D in the pharmaceutical / biotechnology sector has increased over the past few years. According to one particular source, this spending has increased from USD 108 billion in 2006 to USD 145 billion in 2016. Heavy investments are being made towards the discovery of novel approaches for the treatment of various types of cancers. The industry is currently under tremendous pressure not only to meet the expectations of a growing patient population but also to identify ways to address the risks associated with novel drug discovery programs. Over the years, CROs offering drug discovery services have contributed significantly and have now grown to become an integral and indispensable part of the pharmaceutical and biotechnology industry.

 

This study presents an in-depth analysis of a diverse set of companies that offer services across the different steps, such as target identification, target validation, hit generation, hit-to-lead and lead optimization, of the drug discovery process. In addition to other elements, the report features:

  • A discussion on the current state of the market with respect to key players, along with information on the location of headquarters, drug discovery services provided (target identification, target validation, hit generation, hit-to-lead, lead optimization), depth of service portfolio (discovery / preclinical / clinical / commercial manufacturing) and product type (biologics / small molecules).
  • Elaborate profiles of established / emerging players. Each profile features a company overview, financial information, drug discovery service portfolio, recent developments and a view on its future outlook and strategy.
  • An overview of the most active regions in terms of drug discovery services for oncology. The report contains schematic representations of world maps that clearly indicate the location of drug discovery hubs across the world.
  • A comprehensive benchmark analysis, comparing the existing capabilities of various stakeholders within their respective peer groups, to identify ways to become more competitive in the industry. The analysis is based on key parameters such as the depth of service portfolio, the type of molecules researched and the nature of services offered by different companies.
  • An analysis of the agreements that have been established in the recent past, covering drug discovery agreements / research collaborations, license agreements, acquisitions, service alliances and joint venture agreements.
  • A competitive landscape review, featuring a multivariate bubble analysis, based on parameters such as the geographical location, founding year, number of drug discovery services offered and the level of partnering activity in recent years.
  • A discussion on the potential growth areas such as personalized medicines, orphan drugs and complex biopharmaceuticals, and innovative technologies including deep learning solutions and 3D cell culture systems, that are likely to present opportunities or act as growth drivers during the coming years.

 

In addition, the study features a detailed analysis of the existing market size and the future growth potential of the oncology drug discovery services market for the period 2017-2030. We have provided insights on the likely regional evolution of the market, across North America, Europe, China and the rest of the world. Additionally, we have provided informed estimates of the likely market evolution on the basis of type of product (small molecule, biologics) and key steps of drug discovery (target identification, target validation, hit generation, hit-to-lead and lead optimization). In order to account for the uncertainties associated with some of the key parameters, and to add robustness to our model, we have presented three different forecast scenarios, depicting the conservative, base and optimistic tracks of the market’s evolution.

 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of this study, we invited over 100 stakeholders to participate in a survey, in order to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. 

 

Example Highlights

 

  1. During our research, we identified over 115 companies that are actively involved in providing a wide array of oncology drug discovery services; hit-to-lead and lead optimization are amongst the most common services offered by these CROs.
  2. Around 25% of the companies offer end-to-end services for drug discovery, starting from target identification till lead optimization. Examples of such one stop shops include (in alphabetical order) Charles River Laboratories, Evotec, GE Healthcare Life Sciences, GenScript, Lonza, PerkinElmer, Syngene, and TCG Lifesciences.
  3. The current market is characterized by the presence of several established, as well as emerging CROs. Examples of established players with more than 25 years of overall experience in pharmaceutical sector include AMRI, Aurora Fine Chemicals, Cayman Chemical, ChemDiv, Dalton Pharma Services, DavosPharma, Organix, SRI Biosciences and Syncom. Some of the new players that have recently entered this domain include (in alphabetical order) Abzena, Aurelia Bioscience, Envigo, Enzymlogic, HitGen, INOVOTION, New England Discovery Partners and Tybema BioSolutions.
  4. Over 80% of these CROs are located in Europe and North America. It is also worth highlighting that there are several players offering CRO services for oncology drug discovery in certain emerging regions within Asia Pacific, namely India and China. Examples of some of the large-sized CROs based in these locations include (in alphabetical order) Aurigene, GVK Biosciences, Pharmaron, Piramal Pharma Solutions, Sai Life Sciences, ChemPartner and WuXi AppTec.
  5. Although the services offered by these companies range from early drug discovery to drug development and commercialization, there are several companies that solely focus on providing drug discovery services. These include (in alphabetical order) Aquila BioMedical, Aris Pharmaceuticals, Attana, Axxam, Beactica, BellBrook Labs, BioDiscovery Group, CanAm Bioresearch, CreaGen Biosciences, Domainex, Evotec, Exiris, Icagen, Organix, Sapient Discovery, Viva Biotech and Zobio.
  6. The market has witnessed significant partnering activity in the past three years; several CROs have forged strategic alliances with other services providers in order to expand their drug discovery capabilities. We identified over 70 such collaborations, inked specifically for oncology research. Over 30% of the agreements signed by CROs with other players, including drug / therapy developers or academic players, were focused on co-conducting research for the discovery of either therapeutic targets or lead molecules. Such agreements also involved several big pharma giants, such as (in alphabetical order) AbbVie, AstraZeneca, Daiichi Sankyo, Debiopharm Group, MERCK and Sanofi. Recent examples of acquisitions that we came across include Villapharma’s acquisition by Eurofins (January 2017), HD Biosciences’ acquisition by Wuxi AppTec (January 2017), Cyprotex’s acquisition by Evotec (December 2016) and Blue Stream Laboratories’ acquisition by Charles River Laboratories (June 2016).
  7. Driven by the rising demand for novel therapeutic targets and drugs, and the growing importance of contract services, we expect the market to continue on its growth trajectory in the foreseen future. We expect the oncology drug discovery services market to grow at an annualized rate of 6.2%, over the period 2017-2030. In terms of geography, majority (more than 70%) of the share is distributed between North America and Europe; other countries, such as China, are likely to grow at a relatively faster rate in the coming decade.

 

Research Methodology

 

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and type of biopharmaceuticals. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

Chapter Outlines

 

Chapter 2 presents an executive summary of the insights captured in our research. It offers a high level view on the current state of the oncology drug discovery services market, specific factors impacting its growth and how the opportunity is likely to evolve in the mid-long term.

 

Chapter 3 provides an introduction to the drug discovery approach. It includes details on the time taken for a drug to traverse from the bench to the market, along with a historical account of the evolution of the drug discovery process. It also provides an in-depth explanation of each of the five steps involved in the drug discovery process, including details on associated methods / technologies / approaches. Further, the chapter features a discussion on the key challenges associated with conducting drug discovery research in-house, highlighting the need for contract services providers and the evident shift towards outsourcing drug discovery related operations in oncology.

 

Chapter 4 includes a comprehensive overview and analysis of the current market landscape of the oncology drug discovery services market. It features an analysis of drug discovery service providers on the basis of their geographical location, type of drug discovery service provided, depth of service portfolio (discovery / preclinical development / clinical development / commercial manufacturing) and the nature of product (small molecule / biologic).

 

Chapter 5 provides detailed profiles of some of the oncology drug discovery service providers that offer end-to-end services. Each profile features a brief overview of the company, financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

 

Chapter 6 provides detailed profiles of some of the oncology drug discovery service providers that offer target based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

 

Chapter 7 provides detailed profiles of some of the oncology drug discovery service providers that offer lead based services. Each profile features a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

 

Chapter 8 provides detailed profiles of some of the oncology drug discovery service providers that specialize in lead optimization. Each profile features presents a brief overview of the company, its financial information, insights on drug discovery related services offered by the company, recent developments and a comprehensive future outlook.

 

Chapter 9 provides a comprehensive market forecast, depicting how the drug discovery services market for oncology is likely to evolve till 2030. We have presented an analysis of the evolving financial opportunity across various regions, such as North America, Europe, China and ROW. Additionally, we have analyzed the market size based on the nature of molecule (biologic, small molecule) and the key steps of drug discovery (target identification, target validation, hit-to-lead, lead identification and lead optimization). It is worth mentioning that our projections are backed by credible data procured from both secondary and primary sources, and a robust forecast approach validated by in-house and external experts.

 

Chapter 10 provides a detailed benchmark analysis of the companies that provide drug discovery services in the oncology domain. The key parameters considered for this analysis include the depth of the service portfolio, the type of the molecule and the number of services offered by each company within a peer group (based on geography and employee base). The analysis allows the companies to compare their existing capabilities within their peer group and identify opportunities to become more competitive in the industry.

 

Chapter 11 features an elaborate discussion and analysis on the collaborations and partnerships that have been recently inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements in this segment of the overall market. In addition to the aforementioned analysis, the chapter offers an illustrative bubble analysis representing the competitive landscape of players involved in the space, based on their experience, number of drug discovery services offered and the level of activity in terms of collaborations established in the field of oncology research. The key objective of this analysis is to establish a region-wise understanding of contract services offerings and key players involved in the oncology drug discovery market globally.

 

Chapter 12 highlights important trends that are likely to impact CROs providing drug discovery services and influence their efforts to strengthen their presence in this competitive market. During our research, we identified a number of interesting trends, including focus on personalized medicines, orphan drugs and complex biopharmaceuticals, innovative applications of deep learning, use of 3 D cell culture systems and other novel technologies, which are being developed to reduce the innate complexities associated with drug discovery and optimize the time spent on the overall process. We believe that these trends are likely to significantly influence the industry’s evolution over the coming decade.

 

Chapter 13 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

 

Chapter 14 summarizes the overall report. It presents a list of key takeaways and offers our independent opinion on the current market scenario and key trends that are likely to determine how the market is likely to evolve in the mid- and long terms.

 

Chapter 15 is a collection of interview transcripts of the discussions held with some of the key players in this industry. 

 

Chapters 16 is an appendix, which provides tabulated data and numbers for all the figures in the report.

 

Chapter 17 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

 

 
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. Drug Discovery and Development Timeline
3.3. Drug Discovery Process: History and Evolution
3.4. Current Drug Discovery Process
3.5. Drug Discovery Process: Steps Involved
3.5.1 Target Identification: Introduction and Approaches
3.5.1.1. Chemical Proteomic Based Approaches
3.5.1.2. Expression Cloning Techniques
3.5.1.3. In Silico Approach
3.5.2. Target Validation: Introduction and Approaches
3.5.2.1. Pre-genomic Methods
3.5.2.2. Post-genomic Methods
3.5.3. Hit Discovery: Introduction and Approaches
3.5.4. Hit-to-Lead: Introduction and Approaches
3.5.5. Lead Optimization: Introduction and Models
3.6. Challenges Associated With In-House Drug Discovery
3.7. Shift in Trend towards Outsourcing of Drug Discovery Services
3.8. Oncology at the Forefront of Drug Discovery Research
 
4. Market Overview
4.1. Chapter Overview
4.2. Oncology Drug Discovery CROs: Overall Landscape
4.2.1. Oncology Drug Discovery CROs: Distribution by Geography
4.2.2. Oncology Drug Discovery CROs: Distribution by Type of Company
4.2.3. Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
4.2.4. Oncology Drug Discovery CROs: Distribution by Business Model
4.2.5. Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
4.2.6. Oncology Drug Discovery CROs: Distribution by Nature of Molecule
 
5. CROs: End-to-End Service Providers 
5.1. Chapter Overview
5.2. Charles River Laboratories
5.2.1. Company Overview
5.2.2. Key Operations
5.2.3. Financial Performance
5.2.4. Drug Discovery Services
5.2.5. Recent Developments and Future Outlook
 
5.3. Evotec
5.3.1. Company Overview
5.3.2. Key Operations 
5.3.3. Financial Performance
5.3.4. Drug Discovery Services
5.3.5. Recent Developments and Future Outlook
 
5.4. GE Healthcare Life Sciences
5.4.1. Company Overview
5.4.2. Key Operations
5.4.3. Financial Performance
5.4.4. Drug Discovery Services
5.4.5. Recent Developments and Future Outlook
 
5.5. GenScript
5.5.1. Company Overview
5.5.2. Key Operations
5.5.3. Financial Performance
5.5.4. Drug Discovery Services
5.5.5. Recent Developments and Future Outlook
 
5.6. HD Biosciences (A Subsidiary of WuXi AppTec)
5.6.1. Company Overview
5.6.2. Key Operations
5.6.3. Drug Discovery Services
5.6.4. Recent Developments and Future Outlook
 
5.7. Vichem Chemie
5.7.1. Company Overview
5.7.2. Key Operations
5.7.3. Drug Discovery Services
5.7.4. Recent Developments and Future Outlook
 
6. CROs: Target Based Service Providers
6.1. Chapter Overview
6.2. Horizon Discovery
6.2.1. Company Overview
6.2.2. Key Operations
6.2.3. Financial Performance
6.2.4. Drug Discovery Services
6.2.5. Recent Developments and Future Outlook
 
6.3. Mir Lifescience (Division of MIR Group)
6.3.1. Company Overview
6.3.2. Key Operations
6.3.3. Drug Discovery Services
6.3.4. Recent Developments and Future Outlook
 
7. CROs: Hit / Lead Based Service Providers
7.1. Chapter Overview
7.2. DIVERCHIM
7.2.1. Company Overview
7.2.2. Key Operations
7.2.3. Drug Discovery Services
7.2.4. Recent Developments and Future Outlook
 
7.3. GVK Biosciences (A Business Division of GVK)
7.3.1. Company Overview
7.3.2. Key Operations
7.3.3. Financial Performance
7.3.4. Drug Discovery Services
7.3.5. Recent Developments and Future Outlook
 
7.4. NuChem Therapeutics
7.4.1. Company Overview
7.4.2. Key Operations
7.4.3. Drug Discovery Services
7.4.4. Recent Developments and Future Outlook
 
7.5. Prestwick Chemical (A Subsidiary of Bionomics)
7.5.1. Company Overview
7.5.2. Key Operations
7.5.3. Financial Performance
7.5.4. Drug Discovery Services
7.5.5. Recent Developments and Future Outlook
 
7.6. Syncom
7.6.1. Company Overview
7.6.2. Key Operations
7.6.3. Drug Discovery Services
7.6.4. Recent Developments and Future Outlook
 
8. CROs: Lead Optimization Service Providers
8.1. Chapter Overview
8.2. Envigo
8.2.1. Company Overview
8.2.2. Key Operations
8.2.3. Drug Discovery Services
8.2.4. Recent Developments and Future Outlook
 
8.3. Onyx Scientific (A Subsidiary of Ipca Laboratories)
8.3.1. Company Overview
8.3.2. Key Operations
8.3.3. Financial Performance
8.3.4. Drug Discovery Services
8.3.5. Recent Developments and Future Outlook
 
9. Market Sizing and Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Oncology Drug Discovery Services Market, 2017-2030 (USD Billion)
9.4. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Region (USD Billion)
9.4.1. Oncology Drug Discovery Services Market: North America (USD Billion)
9.4.2. Oncology Drug Discovery Services Market: Europe (USD Billion)
9.4.3. Oncology Drug Discovery Services Market: China (USD Billion)
9.4.4. Oncology Drug Discovery Services Market: Rest of the World (USD Billion)
9.5. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule (USD Billion)
9.6. Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service (USD Billion)
 
10. Benchmark Analysis
10.1. Chapter Overview
10.2. Benchmark Analysis: Methodology
10.3. Benchmark Analysis: Peer Groups
10.3.1. Benchmark Analysis: North America, Peer Group I
10.3.2. Benchmark Analysis: North America, Peer Group II
10.3.3. Benchmark Analysis: North America, Peer Group III
10.3.4. Benchmark Analysis: Europe, Peer Group IV
10.3.5. Benchmark Analysis: Europe, Peer Group V
10.3.6. Benchmark Analysis: Europe, Peer Group VI
10.3.7. Benchmark Analysis: Asia Pacific, Peer Group VII
 
11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models
11.3. Oncology Drug Discovery Service Providers: Recent Collaborations
11.3.1. Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 - H1 2017
11.3.2. Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
11.3.3. Oncology Drug Discovery Partnerships: Most Active Players
11.3.4. Oncology Drug Discovery Partnerships: Analysis by Experience, Number of Services and Activity
 
12. Future Growth Opportunities
12.1. Chapter Overview
12.2. Oncology Drug Discovery is on the Cutting Edge of Personalized Medicine
12.3. Growing Popularity of Biologics Demands Specialized Research Expertise
12.4. Orphan Cancer Indications Offer New Opportunities for CROs
12.5. Start-ups in Oncology Will Continue to Seek Increased Support of CROs  
12.6. Technological Advancements to Cater to Complexities Associated with the Drug Discovery Process
12.6.1. Deep Learning Technology
12.6.2. Organoids and 3D Cell Culture Systems
12.6.3. Acoustic Droplet Ejection (ADE) Technology
12.6.4. CRISPR–Cas9 Gene Editing Technology
12.6.5. Cloud Based Technology Platforms
 
13. Survey Analysis
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Type of Drug Discovery Service
13.4. Nature of Molecule
13.5. Depth of Service Portfolio
13.6. Likely Market Size
13.7. Likely Growth Rate
 
14. Conclusion
14.1. Outsourcing has Emerged as a Convenient Option for Drug Discovery and Early Stage Development
14.2. Currently, Europe Stands out as the Major Hub for CROs, followed by North America and Asia Pacific
14.3. Lead Generation and Lead Optimization are the Most Frequently Outsourced Operations
14.4. Flexible Partnership Models have Fostered Collaborations between Drug Developers and CROs
14.5. Innovative Technologies and Untapped Opportunity Areas are Anticipated to Drive Long-Term Growth
14.6. Driven by the growing demand for contract services, the market is expected to witness continuous growth in the foreseen future
 
15. Interview Transcripts
 
16. Appendix 1: Tabulated Data
 
17. Appendix 2: List of Companies and Organizations
 
 
Figure 3.1 Drug Discovery and Development Timeline
 
Figure 3.2 Drug Discovery Process: History and Evolution
 
Figure 3.3 Drug Target: Primary Criteria for Successful Identification
 
Figure 3.4 Drug Discovery Services: Advantages of Outsourcing 
 
Figure 4.1 Oncology Drug Discovery CROs: Distribution by Geography
 
Figure 4.2 Oncology Drug Discovery CROs: Distribution by Country
 
Figure 4.3 Oncology Drug Discovery CROs: Distribution by Type of Company
 
Figure 4.4 Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
 
Figure 4.5 Oncology Drug Discovery CROs: Distribution by Business Model
 
Figure 4.6 Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
 
Figure 4.7 Oncology Drug Discovery CROs: Distribution by Type of Molecule
 
Figure 5.1 Charles River Laboratories: Business Segments
 
Figure 5.2 Charles River Laboratories: Key Operations
 
Figure 5.3 Charles River Laboratories: Revenues, 2012–2016 (USD Billion)
 
Figure 5.4 Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
 
Figure 5.5 Evotec: Key Operations
 
Figure 5.6 Evotec: Revenues, 2013–Q1 2017 (EUR Million)
 
Figure 5.7 Evotec: Revenues by Business Divisions, 2016 (EUR Million)
 
Figure 5.8 Evotec: Drug Discovery Services
 
Figure 5.9 GE Healthcare Life Sciences: Key Operations
 
Figure 5.10 GE Healthcare: Revenues, 2012–2016 (USD Billion)
 
Figure 5.11 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
 
Figure 5.12 GE Healthcare: Drug Discovery Technologies
 
Figure 5.13 GE Healthcare: Cancer Research Tools Used for Drug Discovery Steps
 
Figure 5.14 GenScript: Business Units
 
Figure 5.15 GenScript: Key Operations
 
Figure 5.16 GenScript: Revenues, 2012–2016 (USD Million)
 
Figure 5.17 GenScript: Revenues by Business Divisions, 2016 (USD Million)
 
Figure 5.18 GenScript: Drug Discovery Services
 
Figure 5.19 HD Biosciences: Key Operations
 
Figure 5.20 HD Biosciences: Drug Discovery Services
 
Figure 5.21 Vichem Chemie: Key Operations
 
Figure 6.1 Horizon Discovery: Key Operations
 
Figure 6.2 Horizon Discovery: Revenues, 2012–2016 (GBP Million)
 
Figure 6.3 Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
 
Figure 6.4 Mir Lifescience: Key Operations
 
Figure 7.1 DIVERCHIM: Key Operations
 
Figure 7.2 DIVERCHIM: Drug Discovery Services
 
Figure 7.3 GVK Biosciences: Key Operations
 
Figure 7.4 GVK: Revenues, 2012–2016 (INR Billion)
 
Figure 7.5 NuChem Therapeutics: Key Operations
 
Figure 7.6 NuChem Therapeutics: Drug Discovery Services
 
Figure 7.7 Prestwick Chemical: Key Operations
 
Figure 7.8 Bionomics: Revenues, 2012–2016 (USD Million)
 
Figure 7.9 Syncom: Key Operations
 
Figure 8.1 Envigo: Key Operations
 
Figure 8.2 Onyx Scientific: Key Operations
 
Figure 8.3 Onyx Scientific: Revenues, 2012–2016 (INR Million)
 
Figure 9.1 Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
 
Figure 9.2 Oncology Drug Discovery Services Market, 2017, 2025 and 2030:  Distribution by Region
 
Figure 9.3 Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
 
Figure 9.4 Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
 
Figure 9.5 Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
 
Figure 9.6 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
 
Figure 9.7 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
 
Figure 9.8 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
 
Figure 10.1 Benchmark Analysis: Distribution by Company Size (Number of Employees)
 
Figure 10.2 Benchmark Analysis: North America, Peer Group I
 
Figure 10.3 Benchmark Analysis: North America, Peer Group II
 
Figure 10.4 Benchmark Analysis: North America, Peer Group III
 
Figure 10.5 Benchmark Analysis: Europe, Peer Group IV
 
Figure 10.6 Benchmark Analysis: Europe, Peer Group V
 
Figure 10.7 Benchmark Analysis: Europe, Peer Group VI
 
Figure 10.8 Benchmark Analysis: Asia Pacific, Peer Group VII
 
Figure 11.1 Oncology Drug Discovery Partnerships: Cumulative Trend, 2014 – H1 2017
 
Figure 11.2 Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
 
Figure 11.3 Oncology Drug Discovery Partnerships: Most Active Players 
 
Figure 11.4 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (North America)
 
Figure 11.5 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Europe)
 
Figure 11.6 Oncology Drug Discovery Service Providers: 3-Dimensional Analysis based on Experience, Number of Services and Recent Collaborations (Asia)
 
Figure 12.1 Oncology Drug Discovery Services: Future Growth Opportunities
 
Figure 13.1 Survey Analysis: Distribution by Geography
 
Figure 13.2 Survey Analysis: Seniority Levels of Respondents
 
Figure 13.3 Survey Analysis: Distribution by Type of Drug Discovery Service
 
Figure 13.4 Survey Analysis: Distribution by Nature of Molecule
 
Figure 13.5 Survey Analysis: Distribution by Depth of Service Portfolio
 
Figure 13.6 Survey Analysis: Likely Current Market Size
 
Figure 13.7 Survey Analysis: Likely Growth Rate
 
Figure 14.1 Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
 
 
Table 3.1  Drug Target Classification
 
Table 4.1 Oncology Drug Discovery Service Providers: Details on Geography and Type of Drug Discovery Service
 
Table 4.2  Oncology Drug Discovery Service Providers: Details on Type of CRO, Depth of Service Portfolio and Nature of Molecule
 
Table 5.1 Oncology Drug Discovery: End-to-End Service Providers
 
Table 6.1 Oncology Drug Discovery: Target Based Service Providers
 
Table 7.1 Oncology Drug Discovery: Hit / Lead Based Service Providers
 
Table 8.1 Oncology Drug Discovery: Lead Optimization Service Providers
 
Table 10.1 Benchmark Analysis: Peer Groups
 
Table 11.1 Oncology Drug Discovery Services: Recent Collaborations
 
Table 13.1 Survey Response: Overview of the Participating Companies
 
Table 13.2 Survey Response: Seniority Level of Respondents
 
Table 13.3 Survey Response: Type of Drug Discovery Service
 
Table 13.4 Survey Response: Nature of Molecule
 
Table 13.5 Survey Response: Depth of Service Portfolio
 
Table 13.6 Survey Response: Likely Current Market Size
 
Table 13.7 Survey Response: Likely Growth Rate
 
Table 16.1 Oncology Drug Discovery CROs: Distribution by Country
 
Table 16.2 Oncology Drug Discovery CROs: Distribution by Type of Company
 
Table 16.3 Oncology Drug Discovery CROs: Distribution by Type of Drug Discovery Step
 
Table 16.4 Oncology Drug Discovery CROs: Distribution by Business Model
 
Table 16.5 Oncology Drug Discovery CROs: Distribution by Depth of Service Portfolio
 
Table 16.6 Oncology Drug Discovery CROs: Distribution by Nature of Molecule
 
Table 16.7 Charles River Laboratories: Revenues, 2012–2016 (USD Billion)
 
Table 16.8 Charles River Laboratories: Revenues by Business Divisions, 2016 (USD Million)
 
Table 16.9 Evotec: Revenues, 2013–Q1 2017 (EUR Million)
 
Table 16.10 Evotec: Revenues by Business Divisions, 2016 (EUR Million)
 
Table 16.11 GE Healthcare: Revenues, 2012 – 2016 (USD Billion)
 
Table 16.12 GE Healthcare: Revenues by Business Divisions, 2016 (USD Billion)
 
Table 16.13 GenScript: Revenues, 2012 – 2016 (USD Million)
 
Table 16.14 GenScript: Revenues by Business Divisions, 2016 (USD Million)
 
Table 16.15 Horizon Discovery: Revenues, 2012 – 2016 (GBP Million)
 
Table 16.16 Horizon Discovery: Revenues by Business Segments, 2016 (GBP Million)
 
Table 16.17 GVK: Revenues, 2012–2016 (INR Billion)
 
Table 16.18 Bionomics: Revenues, 2012–2016 (USD Million)
 
Table 16.19 Onyx Scientific: Revenues, 2012–2016 (INR Million)
 
Table 16.20 Oncology Drug Discovery Services Market, 2017-2030: Conservative Scenario (USD Billion)
 
Table 16.21 Oncology Drug Discovery Services Market, 2017-2030: Base Scenario (USD Billion)
 
Table 16.22 Oncology Drug Discovery Services Market, 2017-2030: Optimistic Scenario (USD Billion)
 
Table 16.23 Oncology Drug Discovery Services Market, 2017, 2025 and 2030:  Distribution by Region (%)
 
Table 16.24 Oncology Drug Discovery Services Market, 2017-2030: North America, Conservative Scenario (USD Billion)
 
Table 16.25 Oncology Drug Discovery Services Market, 2017-2030: North America, Base Scenario (USD Billion)
 
Table 16.26 Oncology Drug Discovery Services Market, 2017-2030: North America, Optimistic Scenario (USD Billion)
 
Table 16.27 Oncology Drug Discovery Services Market, 2017-2030: Europe, Conservative Scenario (USD Billion)
 
Table 16.28 Oncology Drug Discovery Services Market, 2017-2030: Europe, Base Scenario (USD Billion)
 
Table 16.29 Oncology Drug Discovery Services Market, 2017-2030: Europe, Optimistic Scenario (USD Billion)
 
Table 16.30 Oncology Drug Discovery Services Market, 2017-2030: China, Conservative Scenario (USD Billion)
 
Table 16.31 Oncology Drug Discovery Services Market, 2017-2030: China, Base Scenario (USD Billion)
 
Table 16.32 Oncology Drug Discovery Services Market, 2017-2030: China, Optimistic Scenario (USD Billion)
 
Table 16.33 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Conservative Scenario (USD Billion)
 
Table 16.34 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Base Scenario (USD Billion)
 
Table 16.35 Oncology Drug Discovery Services Market, 2017-2030: Rest of the World, Optimistic Scenario (USD Billion)
 
Table 16.36 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Conservative Scenario (USD Billion)
 
Table 16.37 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Base Scenario (USD Billion)
 
Table 16.38 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Nature of Molecule, Optimistic Scenario (USD Billion)
 
Table 16.39 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Conservative Scenario (USD Billion)
 
Table 16.40 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Base Scenario (USD Billion)
 
Table 16.41 Oncology Drug Discovery Services Market, 2017-2030: Distribution by Type of Service, Optimistic Scenario (USD Billion)
 
Table 16.42 Benchmark Analysis: Distribution by Company Size (Number of Employees)
 
Table 16.43 Oncology Drug Discovery Partnerships: Cumulative Trends
 
Table 16.44 Oncology Drug Discovery Partnerships: Distribution by Type of Partnership
 
Table 16.45 Oncology Drug Discovery Partnerships: Most Active Players
 
Table 16.46 Survey Analysis: Distribution by Geography
 
Table 16.47 Survey Analysis: Seniority Levels of Respondents
 
Table 16.48 Survey Analysis: Distribution by Type of Drug Discovery Service
 
Table 16.49 Survey Analysis: Distribution by Nature of Molecule
 
Table 16.50 Survey Analysis: Distribution by Depth of Service Portfolio
 
Table 16.51 Survey Analysis: Likely Current Market Size
 
Table 16.52 Survey Analysis: Likely Growth Rate
 
Table 16.53 Oncology Drug Discovery Services Market, 2017, 2022 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)
 

The following companies and organizations have been mentioned in the report:

  1. AbbVie
  2. Abzena
  3. Academic Medical Center Helsinki
  4. Actelion Pharmaceuticals
  5. ActivX Biosciences
  6. Addex Therapeutics
  7. Advinus Therapeutics
  8. Agilux Laboratories
  9. Agios Pharmaceuticals
  10. Albany Molecular Research 
  11. AlphaGene
  12. AmorChem
  13. AnCoreX Therapeutics
  14. Anthem Biosciences
  15. APEIRON Biologics
  16. Aptuit
  17. Aquila BioMedical 
  18. Aragen Bioscience
  19. Aris Pharmaceuticals
  20. ArQule
  21. Asahi Kasei Pharma 
  22. Asclepia MedChem Solutions
  23. AsisChem
  24. Astex Therapeutics
  25. AstraZeneca
  26. Attana
  27. Aurelia Bioscience
  28. Aurigene
  29. Aurora Fine Chemicals
  30. Avvinity 
  31. Axon Biochemicals
  32. Axon Medchem
  33. Axxam
  34. Babraham Institute 
  35. Bayer Group
  36. Beactica
  37. BellBrook Labs
  38. Beryllium Discovery
  39. Bienta 
  40. Biobide
  41. Biocon 
  42. BioDiscovery Group
  43. BioDuro
  44. BioFocus DPI
  45. Biomedicum Genomics 
  46. BioMotiv
  47. Bionaturis Group
  48. Bionomics 
  49. BioNTech
  50. BioStructures
  51. Birkbeck College
  52. Blue Stream Laboratories
  53. British Columbia Cancer Agency
  54. C4X Discovery
  55. Cadiz University  
  56. California Institute for Biomedical Research 
  57. Caliper Life Sciences
  58. CanAm Bioresearch
  59. Cancer Research Technology
  60. Cancer Research UK
  61. Carrick Therapeutics
  62. Cayman Chemical
  63. Celgene 
  64. Celsis Group
  65. Centauri Therapeutics
  66. Centro Nacional de Investigaciones Oncológicas
  67. Charles River Laboratories
  68. Charnwood Molecular
  69. ChemBridge
  70. ChemDiv
  71. ChemoGenics BioPharma
  72. Chemveda Life Sciences
  73. Child Health and Development Institute of Connection
  74. Clininvent 
  75. CombinatoRx
  76. Confluence Discovery Technologies
  77. Covance
  78. CreaGen Biosciences
  79. CRELUX
  80. CrownBio
  81. Curadev Pharma
  82. Curis
  83. Cyprotex
  84. Dabur Group
  85. Dabur Research Foundation
  86. Daiichi Sankyo
  87. Dalton Pharma Services
  88. Dana-Farber Cancer Institute
  89. DavosPharma
  90. Debiopharm Group
  91. DIVERCHIM
  92. Domainex
  93. Dong-A ST
  94. Dr. Reddy’s Laboratories 
  95. École Polytechnique Fédérale de Lausanne
  96. EDELRIS
  97. Enamine
  98. Envigo
  99. Enzymlogic
  100. Epichem
  101. Epistem
  102. Eurofins Scientific
  103. Evotec
  104. Exiris
  105. Exquiron Biotech
  106. Exscientia
  107. Fannin Innovation Studio
  108. Felicitex Therapeutics
  109. FORMA Therapeutics
  110. Free University of Amsterdam
  111. Fusion Antibodies 
  112. Galapagos
  113. GalChimia
  114. Galectin Therapeutics
  115. GE Healthcare Life Sciences
  116. Genentech
  117. Genomics Medicine Ireland
  118. GenScript
  119. GL Chemtec International 
  120. GlaxoSmithKline 
  121. Griffith University
  122. GVK Biosciences
  123. H3 Biomedicine
  124. Harlan Laboratories
  125. HD Biosciences
  126. Helmholtz Association
  127. HitGen
  128. Horizon Discovery
  129. HQL Pharmaceuticals
  130. Huntingdon Life Sciences
  131. Icagen
  132. iGEM
  133. Infinity Pharmaceuticals
  134. INOVOTION
  135. Inserm
  136. Insilico Medicine
  137. Institut du cancer de Montréal
  138. Institute for Research in Immunology and Cancer Commercialization of Research
  139. Institute of Cancer Research, London
  140. INTEGREX Research
  141. IntelliSyn
  142. IOTA Pharmaceuticals
  143. Ipca Laboratories
  144. Jagiellonian University
  145. Janssen Biotech
  146. Janssen Pharmaceuticals
  147. Jinan Nornoon Biological Engineering 
  148. Johnson & Johnson
  149. Joseph Fourier University
  150. JPT Peptide Technologies
  151. Jubilant Biosys
  152. Jubilant Life Sciences 
  153. Juniper Pharma Services
  154. Juno Therapeutics
  155. KYORIN Pharmaceutical
  156. LabCorp
  157. Lead Discovery Center
  158. Leiden University
  159. Longthera Pharmaceuticals
  160. Lonza
  161. Marshall University
  162. Mascot Industries
  163. Max Planck Innovation
  164. Max Planck Institute of Biochemistry
  165. Medicilon
  166. Medivir
  167. Memorial Sloan Kettering Cancer Center
  168. Mercachem
  169. Merck Serono
  170. Merck Sharpe & Dohme 
  171. Mir Lifescience
  172. Mirimus
  173. Moderna Therapeutics 
  174. n3D Biosciences
  175. Nanjing Biotech Innovation Corporation
  176. Nanjing Legend Biotechnology
  177. Nanosyn
  178. National Cancer Institute
  179. National Resource Center for Mutant Mice
  180. National University of Singapore 
  181. NEOMED Institute
  182. New England Discovery Partners 
  183. Nile Scan & Labs 
  184. Nimbus Therapeutics
  185. NovAliX
  186. NuChem Therapeutics
  187. OcellO
  188. Oncompass Medicine
  189. Oncotest 
  190. Oncotyrol
  191. Ontario Institute for Cancer Research
  192. Onyx Scientific
  193. Organix
  194. OriBase Pharma
  195. Orion Corporation 
  196. OTAVAchemicals
  197. OXELTIS
  198. Oxford Bioscience Partners
  199. Oxford University
  200. Paraza Pharma
  201. Paterson Institute for Cancer Research
  202. Pepscan
  203. PerkinElmer
  204. Pfizer
  205. Pharmaceutical Product Development
  206. PharmAgra Labs
  207. Pharmaron
  208. Pharminox
  209. PHENOMIN-ICS
  210. Piramal Pharma Solutions 
  211. Prestwick Chemical
  212. Proteros
  213. Provid Pharmaceuticals
  214. Queen’s University Belfast
  215. Quotient Bioresearch
  216. Qurient
  217. Radboud University
  218. Ratnamani Healthcare
  219. Reach Separations
  220. Red Glead Discovery 
  221. Redx Pharma
  222. Regen BioPharma
  223. Roche
  224. RTI International
  225. Sage Laboratories
  226. Sai Life Sciences
  227. SAMDI Tech
  228. Sanofi 
  229. Sapient Discovery
  230. SARomics Biostructures 
  231. SBH Sciences
  232. Schrödinger
  233. Selcia
  234. Selvita
  235. Semmelweis University
  236. Shanghai ChemPartner
  237. ShangPharma 
  238. Shionogi
  239. SRI Biosciences
  240. Stanford University
  241. Sundia MediTech
  242. Sygnature Discovery
  243. Syncom Healthcare
  244. Syngene
  245. Synvolux Therapeutics
  246. Taros Chemicals
  247. TATA Group
  248. Tata Trusts 
  249. TC Scientific
  250. TCG Lifesciences
  251. The Agency for Science, Technology and Research
  252. The Eskitis Institute for Drug Discovery
  253. The European Molecular Biology Laboratory 
  254. The Milner Therapeutics Institute
  255. The Ohio State University Comprehensive Cancer Center
  256. The Rockefeller University
  257. The Scripps Research Institute 
  258. The University Medical Center Groningen
  259. The University of Texas MD Anderson Cancer Center 
  260. The Wellcome Trust Sanger Institute
  261. Thermo Fisher Scientific
  262. Translational Drug Development
  263. Translational Genomics Research Institute
  264. Tri-Institutional Therapeutics Discovery Institute 
  265. Tybema BioSolutions
  266. UbiQ
  267. Ubiquigent
  268. UCB Biopharma
  269. United BioPharma 
  270. Univalor 
  271. University College London
  272. University of California, Berkeley
  273. University of Cambridge
  274. University of Montreal
  275. University of Strasbourg
  276. University of Tsukuba
  277. University of Wisconsin-Madison: School of Pharmacy
  278. Vanta Bioscience
  279. Vichem Chemie
  280. Villapharma Research
  281. ViroStatics
  282. Viva Biotech
  283. Wageningen University
  284. Weill Cornell Medicine
  285. WIL Research
  286. WuXi AppTec
  287. York University
  288. Zenith Technologies 
  289. ZoBio
 

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security